Learn about cutting-edge science and gain life-enhancing insights.

Press Release

atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the…

Press Release

ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the…

News

ATAI’s Chief Scientific Officer joins leaders in psychedelic medicine at Mapping the Mind

Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in…

News

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

NEWPORT BEACH, CA and BERLIN, GERMANY – Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI…

Press Release

ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

Today, ATAI Life Sciences, a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of…

News

Gender Disparities and Mental Health Risk Factors

We’re social creatures: We not only desire interaction with others but actually need it. Contact with others — particularly physical contact —…

Press Inquiries

ATAI Life Sciences is a global biotech company builder. Based in Berlin, New York and Amsterdam, our vision is to ultimately cure mental health disorders, enabling people to live healthier and happier lives.

GET IN TOUCH
JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit